News

Video

Trastuzumab Deruxtecan (T-DXd) vs Physician’s Choice of Chemotherapy (TPC) in Patients (pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy (ET): Primary Results From DESTINY-Breast06 (DB-06)

Author(s):

Aditya Bardia, MD, MPH

Dr. Aditya Bardia presents the findings of DESTINY-Breast06 (NCT04494425) in chemotherapy naive patients with HER2-low and HER2-ultra low metastatic breast cancer demonstrating progression-free survival of trastuzumab deruxtecan compared to chemotherapy treatment of physician’s choice.

Related Videos
Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH
Linda Vahdat, MD, MBA
Peter Forsyth, MD
Bruce G. Haffty, MD, MS, FACR, FASTRO
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Related Content
The OncFive: Top Oncology Articles for the Week of 8/25
August 31st 2024

The OncFive: Top Oncology Articles for the Week of 8/25

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD
August 29th 2024

State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

Shipra Gandhi, MD
August 26th 2024

CDK4/6 Inhibitors, ADCs, and PI3K Inhibitors Individualize HR+ Breast Cancer Management

Bruce G. Haffty, MD, MS
August 25th 2024

NSABP B-51 Data Highlight Evolving Role of Radiation in Early-Stage Breast Cancer